Hardy, JA, Higgins, GA. Alzheimer's disease: the amyloid cascade
1992; 256: 184–5.
Drachman, DA. The amyloid hypothesis, time to move on: amyloid is
the downstream result, not cause, of Alzheimer's disease.
2014; 10: 372–80.
Selkoe, DJ. The molecular pathology of Alzheimer's
1991; 6: 487–98.
Hardy, J, Allsop, D. Amyloid deposition as the central event in the
aetiology of Alzheimer's disease. Trends
1991; 12: 383–8.
Tanzi, RE. The genetics of Alzheimer disease.
Cold Spring Harb Perspect Med
Sambamurti, K, Vasudevaraju, P, Mintzer, J, Bachman, D, Granholm, C. Can the failure of Alzheimer's disease clinical
trials be stepping stones to ultimate success: is the amyloid hypothesis
discredited by animal models. J Alzheimers Dis
2012; 2: e115.
Jack, CR, Knopman, DS, Jagust, WJ, Shaw, LM, Aisen, PS, Weiner, MW, et al. Hypothetical model of dynamic biomarkers of
the Alzheimer's pathological cascade. Lancet
2010; 9: 119–28.
Rodrigue, KM, Kennedy, KM, Devous, MD, Rieck, JR, Hebrank, AC, Diaz-Arrastia, R, et al. β-Amyloid burden in healthy aging: regional
distribution and cognitive consequences.
2012; 78: 387–95.
Braak, H, Braak, E. Frequency of stages of Alzheimer-related lesions in
different age categories. Neurobiol
1997; 18: 351–7.
Jack, CR, Knopman, DS, Jagust, WJ, Petersen, RC, Weiner, MW, Aisen, PS, et al. Tracking pathophysiological processes in
Alzheimer's disease: an updated hypothetical model of dynamic
biomarkers. Lancet Neurol
2013; 12: 207–16.
Karran, E, Mercken, M, De Strooper, B. The amyloid cascade hypothesis for Alzheimer's
disease: an appraisal for the development of
therapeutics. Nat Rev Drug Discov
Harold, D, Abraham, R, Hollingworth, P, Sims, R, Gerrish, A, Hamshere, ML, et al. Genome-wide association study identifies
variants at CLU and PICALM associated
with Alzheimer's disease. Nat Genet
2009; 41: 1088–93.
Doody, RS, Raman, R, Farlow, M, Iwatsubo, T, Vellas, B, Joffe, S, et al. A phase 3 trial of semagacestat for treatment
of Alzheimer's disease. N Engl J Med
2013; 369: 341–50.
Gilman, S, Koller, M, Black, RS, Jenkins, L, Griffith, SG, Fox, NC, et al. Clinical effects of Aβ immunization (AN1792)
in patients with AD in an interrupted trial.
2005; 64: 1553–62.
Karran, E, Hardy, J. A critique of the drug discovery and phase 3
clinical programs targeting the amyloid hypothesis for Alzheimer
disease. Ann Neurol
Toyn, JH, Ahlijanian, MK. Interpreting Alzheimer's disease clinical trials in
light of the effects on amyloid-β. Alzheimers Res
2014; 6: 14.
Sperling, RA, Aisen, PS, Beckett, LA, Bennett, DA, Craft, S, Fagan, AM, et al. Toward defining the preclinical stages of
Alzheimer's disease: Recommendations from the National Institute on
Aging–Alzheimer's Association workgroups on diagnostic guidelines for
Alzheimer's disease. Alzheimers Dement
2011; 7: 280–92.
Hyman, BT, Sorger, P. Failure analysis of clinical trials to test the
amyloid hypothesis. Ann Neurol
2014; 76: 159–61.
Choi, SH, Kim, YH, Hebisch, M, Sliwinski, C, Lee, S, D'Avanzo, C, et al. A three-dimensional human neural cell culture
model of Alzheimer/'s disease. Nature
2014; 515: 274–8.
Vellas, B, Carrillo, MC, Sampaio, C, Brashear, HR, Siemers, E, Hampel, H, et al. Designing drug trials for Alzheimer's
disease: what we have learned from the release of the phase III antibody
trials: a report from the EU/US/CTAD Task Force.
2013; 9: 438–44.
Sperling, RA, Rentz, DM, Johnson, KA, Karlawish, J, Donohue, M, Salmon, DP, et al. The A4 study: stopping AD before symptoms
Sci Transl Med
Mullard, A. Sting of Alzheimer's failures offset by upcoming
prevention trials. Nat Rev Drug Discov
2012; 11: 657–60.